Patents Assigned to Sankyo Company Limited
-
Patent number: 10208082Abstract: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.Type: GrantFiled: September 9, 2015Date of Patent: February 19, 2019Assignee: Daiichi Sankyo Company, LimitedInventors: Yuji Kasuya, Yasuhiro Nakagami, Emiko Hatano, Tatsuya Inoue, Kazuhiro Yoshida, Satoshi Komoriya, Yoko Murakami, Masaru Iwasaki, Atsunobu Sakamoto, Kayoko Masuda, Masako Minami, Mayumi Iizuka, Yasunori Ono, Takashi Ohnuki
-
Patent number: 10202606Abstract: The present invention provides an oligodeoxynucleotide containing humanized K type CpG oligodeoxynucleotide and poly deoxyadenylate, wherein the poly deoxyadenylate is placed on the 3?-side of the humanized K type CpG oligodeoxynucleotide. In addition, the present invention provides a complex containing the aforementioned oligodeoxynucleotide and ?-1,3-glucan.Type: GrantFiled: September 19, 2014Date of Patent: February 12, 2019Assignees: NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION, DAIICHI SANKYO COMPANY, LIMITEDInventors: Ken Ishii, Kouji Kobiyama, Taiki Aoshi, Fumihiko Takeshita, Yuji Kasuya, Takako Niwa, Makoto Koizumi
-
Patent number: 10195288Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.Type: GrantFiled: October 10, 2013Date of Patent: February 5, 2019Assignee: Daiichi Sankyo Company, LimitedInventors: Takeshi Masuda, Hiroyuki Naito, Takashi Nakada, Masao Yoshida, Shinji Ashida, Hideki Miyazaki, Yuji Kasuya, Koji Morita, Yuki Abe, Yusuke Ogitani
-
Patent number: 10189804Abstract: It is an object of the present invention to provide an excellent method for producing an excellent therapeutic agent. The solution of the present invention is as shown in the following scheme: wherein R1 represents a C1-C6 alkyl group, R2 represents a C1-C6 alkyl group, and R3 represents a C1-C6 alkyl group.Type: GrantFiled: April 22, 2016Date of Patent: January 29, 2019Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Masayuki Murakami, Yuichi Aki, Daisuke Fukatsu, Kenichi Kimura, Makoto Michida, Koji Hamaoka
-
Publication number: 20190010450Abstract: The present invention relates to an isolated mesenchymal stem cell-like human multipotent stem cell population characterized by being EphA7 positive, medical materials containing the cell population, and a method for producing the cell population comprising separating EphA7-positive cells from adherent cells derived from a tissue comprising capillary vessels.Type: ApplicationFiled: July 29, 2016Publication date: January 10, 2019Applicants: National University Corporation ASAHIKAWA MEDICAL UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITEDInventors: Junichi KAWABE, Taiji NAGAOKA, Akitoshi YOSHIDA, Naoyuki HASEBE
-
Publication number: 20190008981Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.Type: ApplicationFiled: September 26, 2018Publication date: January 10, 2019Applicant: Daiichi Sankyo Company, LimitedInventors: Takeshi Masuda, Hiroyuki Naito, Takashi Nakada, Masao Yoshida, Shinji Ashida, Hideki Miyazaki, Yuji Kasuya, Koji Morita, Yuki Abe, Yusuke Ogitani
-
Patent number: 10172806Abstract: An object of the present invention is to provide a pharmaceutical composition having abuse deterrent properties and thereby prevent the abuse of a pharmacologically active component by an abuser (abuse through snorting, abuse through injection, or abuse through snorting or injection of a temporarily extracted drug). The present invention provides a pharmaceutical composition having abuse deterrent properties that possesses both a physical barrier and a chemical barrier to being abused by an abuser, a method for producing the same and a method for using the same.Type: GrantFiled: June 14, 2017Date of Patent: January 8, 2019Assignee: Daiichi Sankyo Company, LimitedInventors: Shuichi Yada, Ryoichi Hayakawa, Atsutoshi Ito, Hideki Yano
-
Patent number: 10174035Abstract: The present invention relates to a pyrazole derivative of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof, stereoisomer thereof or a deuterium form thereof, wherein, n, Y, Ra, R1, R2, R3, R4, R5 and R6 are as defined hereinafter in the specification, a pharmaceutical composition comprising a compound of formula (I) as an active ingredient, methods of production, and methods of use thereof. Particularly, the present invention provides a compound of formula (I) as inhibitors of phosphatidylinositol-3-kinase (PI3K), which can be used for treating or preventing inflammatory, autoimmune, orphan and hyperproliferative disease and disorder.Type: GrantFiled: March 29, 2016Date of Patent: January 8, 2019Assignee: Daiichi Sankyo Company, LimitedInventors: Kirandeep Kaur Samby, Yogesh Baban Surase, Sagar Ramdas Amale, Suresh Kumar Gorla, Priyanka Patel, Ashwani Kumar Verma
-
Publication number: 20190000847Abstract: The present invention provides a therapeutic agent for a wound comprising a compound represented by the formula (I) wherein R1 represents a hydroxy C1-C6 alkyl group, a C2-C7 alkanoyl group, a C2-C7 alkanoyl C1-C6 alkyl group, a (C1-C6 alkoxy)carbonyl group, a (C1-C6 alkoxy)carbonyl C1-C6 alkyl group, a carboxy group, or a carboxy C1-C6 alkyl group, or a pharmacologically acceptable salt thereof as an active ingredient.Type: ApplicationFiled: December 15, 2016Publication date: January 3, 2019Applicant: DAIICHI SANKYO COMPANY LIMITEDInventor: Ken ISHII
-
Patent number: 10155821Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.Type: GrantFiled: July 28, 2016Date of Patent: December 18, 2018Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki Naito, Yusuke Ogitani, Takeshi Masuda, Takashi Nakada, Masao Yoshida, Shinji Ashida, Koji Morita, Hideki Miyazaki, Yuji Kasuya, Ichiro Hayakawa, Yuki Abe
-
TABLET, METHOD OF PRODUCING TABLET, TABLET MANAGEMENT DEVICE, TABLET VERIFICATION DEVICE AND PROGRAM
Publication number: 20180350058Abstract: A method of producing a tablet in which an uncoated tablet is coated by a coating agent, the method including: a coating process of coating uncoated tablets with a coating agent by spray coating the coating agent onto tablets that are churned and tumbled inside a container, and drying the tablets inside the container by supplying drying air into the container and exhausting air from the container, wherein spray coating conditions, including air supply temperature, air supply rate, and spray speed, are controlled according to the weight of the coating agent with which the uncoated tablets are coated, such that the humidity of air exhausted during spray coating is within a range of from 14% RH to 30% RH.Type: ApplicationFiled: August 13, 2018Publication date: December 6, 2018Applicants: FUJI XEROX CO., LTD., DAIICHI SANKYO COMPANY, LIMITEDInventors: Kensuke ITO, Yasuhiro SUZUKI -
Patent number: 10139415Abstract: Provided are: a method of predicting sensitivity to a molecularly targeted drug; a method of selecting a patient who is determined to have high responsiveness to administration of a drug; and a reagent to be used in these methods.Type: GrantFiled: February 27, 2014Date of Patent: November 27, 2018Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventor: Masaki Kiga
-
Patent number: 10138240Abstract: A crystal of a compound represented by the general formula (I) or a pharmacologically acceptable salt thereof has an excellent LCAT-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-HDL-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein R1 is a hydrogen atom or a hydroxy group, and R is a 2-(trifluoromethyl)pyrimidin-5-yl group or a 5-(trifluoromethyl)pyrazin-2-yl group.Type: GrantFiled: June 10, 2016Date of Patent: November 27, 2018Assignee: Daiichi Sankyo Company, LimitedInventors: Katsuhiro Kobayashi, Toshio Kaneko
-
Publication number: 20180327511Abstract: The present invention relates to an antibody that binds to GARP and is useful as a therapeutic agent for a tumor, and a method for treating a tumor using the aforementioned antibody. It is an object of the present invention to provide an antibody, which inhibits the function of Treg in a tumor and is thereby used as a pharmaceutical product having therapeutic effects, a method for treating a tumor using the aforementioned antibody, and the like. An anti-GARP antibody that binds to GARP and exhibits inhibitory activity to Treg function and exhibits ADCC activity is obtained, and moreover a pharmaceutical composition for use in tumor therapy, comprising the aforementioned antibody, etc. is obtained.Type: ApplicationFiled: July 24, 2018Publication date: November 15, 2018Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Kazuki SATOH, Kazuki HIRAHARA, Ichiro WATANABE, Masato AMANO
-
Publication number: 20180327399Abstract: Problem to be Solved There is a need for a new antibiotic having a novel mechanism of action which exhibit strong antibacterial activity not only against sensitive bacteria but also against resistant bacteria thereof, and at the same time possesses excellent solubility an a safety profile amenable to human use. Solution to the Problem As a result of intensive research, the present inventors have found that a compound represented by general formula (I), a stereoisomer, or a pharmaceutically acceptable salt thereof inhibits DNA gyrase GyrB subunit and/or topoisomerase IV ParE subunit possesses excellent solubility and a safety profile for use in humans for the treatment of bacterial infectious diseases.Type: ApplicationFiled: September 28, 2016Publication date: November 15, 2018Applicant: Daiichi Sankyo Company, LimitedInventors: Manoj Kumar Khera, Tarun Mathur, Jitendra A. Sattigeri, Nobuhisa Masuda, Tsuyoshi Soneda, Yoshiko Kagoshima, Toshiyuki Konosu, Tetsuya Suzuki, Makoto Yamaoka, Ryo Itooka
-
Patent number: 10117952Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.Type: GrantFiled: October 10, 2013Date of Patent: November 6, 2018Assignee: Daiichi Sankyo Company, LimitedInventors: Takeshi Masuda, Hiroyuki Naito, Takashi Nakada, Masao Yoshida, Shinji Ashida, Hideki Miyazaki, Yuji Kasuya, Koji Morita, Yuki Abe, Yusuke Ogitani
-
Patent number: 10118972Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.Type: GrantFiled: July 28, 2016Date of Patent: November 6, 2018Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki Naito, Yusuke Ogitani, Takeshi Masuda, Takashi Nakada, Masao Yoshida, Shinji Ashida, Koji Morita, Hideki Miyazaki, Yuji Kasuya, Ichiro Hayakawa, Yuki Abe
-
Publication number: 20180311278Abstract: The problem with which the present invention is concerned is providing a novel pharmaceutical preparation, the restrictions on the administration of which to a patient are more relaxed than those of a conventional spherical carbon adsorbent, which can be simultaneously taken with other drugs and, moreover, which is reduced in dosage. The problem can be solved by a pharmaceutical preparation for oral administration comprising a porous material, wherein a means for exposing a surface of the porous material for the first time in the large intestine or a lower part of the small intestine is provided on the porous material.Type: ApplicationFiled: October 25, 2016Publication date: November 1, 2018Applicant: Daiichi Sankyo Company, LimitedInventors: Koji Matsumoto, Tomomi Yoshitomi, Naomi Tanaka, Kazuhiro Yoshida, Yuji Kasuya, Masaoki Ohya
-
Patent number: 10112908Abstract: A method for producing a compound (4), which comprises allowing a compound (1) to react with hydrogen gas in an inert solvent, in the presence of a specific chiral ligand and a ruthenium catalyst, or in the presence of an asymmetric transition metal complex catalyst previously generated from the chiral ligand and the ruthenium catalyst.Type: GrantFiled: September 17, 2015Date of Patent: October 30, 2018Assignee: DAICHI SANKYO COMPANY, LIMITEDInventors: Masaki Hayashi, Kazutoshi Ukai
-
Patent number: 10111858Abstract: A pharmaceutical for the prophylaxis or treatment of hypertension or a disease derived from hypertension. The pharmaceutical is characterized by comprising (i) a specific mineralocorticoid receptor antagonist and (ii) one or more components selected from the following components (A) to (C), for administration simultaneously or separately at a time interval: (A) an angiotensin II receptor antagonist, (B) a calcium antagonist, and (C) a diuretic.Type: GrantFiled: October 2, 2017Date of Patent: October 30, 2018Assignee: Daiichi Sankyo Company, LimitedInventors: Kiyoshi Arai, Tsuyoshi Homma, Makoto Mizuno